Loading patent…
AssigneeLyell Immunopharma, Inc.
InventorsRaul E. Vizcardo Sakoda, Nicholas Restifo, Richard D. Klausner, Yin Huang, Takuya Maeda, Naritaka Tamaoki, Yasuhiro Yamazaki
Estimating the term…
The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.
A method of producing rejuvenated T cells, comprising
2-4. (canceled)
6-7. (canceled)
12-13. (canceled)
(canceled)
29-32. (canceled)
(canceled)
A method of producing T cells, comprising
A population of T cells whose epigenetic age is at least 5% younger than its chronological age.
(canceled)
A population of T cell derived adherent cells, wherein at least 70% of the cells express CD3 and SSEA4.
46-48. (canceled)
A population of T cell derived adherent cells, wherein at least 30% of the cells express CD9 or CD90.
(canceled)
52-53. (canceled)
A population of T cells produced by a method comprising
56-90. (canceled)
92-95. (canceled)
A method of producing a rejuvenated tumor infiltrating lymphocyte (TIL), comprising:
(canceled)
A method of producing rejuvenated tumor infiltrating lymphocytes (TILs), comprising
102-104. (canceled)
(canceled)
(canceled)
111-112. (canceled)
Dependencies are inferred from the claim text.